Zenith Renu G36135Recalls & reported problems
Cook Incorporated · Zenith Renu, AAA Ancillary Graft Main Body Extension · Class 3 · Implant
Data updated Oct 16, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 10827002361352), received between Dec 29, 2017 and Dec 29, 2017 — classified as 1 injury.
The most frequently reported specific device problem is “Activation, Positioning or Separation Problem” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.
Most reported problems
Device problems
- Activation, Positioning or Separation Problem1
Patient problems
- No Code Available1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjuryDec 29, 2017Activation, Positioning or Separation Problem; Activation, Positioning or Separation Problem
IT WAS REPORTED THAT THE ZENITH RENU AAA ANCILLARY GRAFT MAIN BODY EXTENSION "DID NOT OPEN AS EXPECTED AND THE FINAL ANGIOGRAM SHOWED THAT THE RIGHT LOWER RENAL ARTERY WAS PARTIALLY COVERED. THE RX1 26-62 WAS INSERTED AND THE PROXIMAL GOLD MARKERS WERE PLACED CORRECTLY IN RESPECT OF THE LOWER RIGHT RENAL ARTERY, APPROXIMATELY 4 MM INFERIOR TO MOST INFERIOR RENAL ARTERY. THE DEPLOYMENT WAS COMPLETED PER THE INSTRUCTIONS FOR USE AND THERE WAS NO OFF LABEL USE OF THE DEVICE. THE FINAL ANGIOGRAM SHOWED UP WITH A PARTIAL COVERING OF THE RIGHT, LOWER RENAL ARTERY. FORTUNATELY, THE SURGEON WAS ABLE TO PRESERVE FLOW TO THE RENAL ARTERY BY INTRODUCING A STENT INTO THE RENAL ARTERY. NO ADDITIONAL ADVERSE EFFECTS TO THE PATIENT WERE REPORTED.
Patient problems: No Code Available
MAUDE report 7155071 ↗
Other SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT devices
- Endurant® IIs ESBF2814C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls34 deaths254 reports
- Endurant® IIs ESBF3214C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls19 deaths173 reports
- Endurant® IIs ESBF3614C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT1 recall37 deaths214 reports
- Endurant® IIs ESBF2514C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls18 deaths136 reports
- Endurant® IIs ESBF2314C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls9 deaths60 reports
- RelayPro Thoracic Stent-Graft System 28-N4-34-154-34UBolton Medical Inc. · System, Endovascular Graft, Aortic Aneurysm Treatment3 recalls7 reports
- Vela Proximal Endograft System A34-34/C100-O20 VEndologix LLC · System, Endovascular Graft, Aortic Aneurysm Treatment3 deaths152 reports
- Endurant® II ETCF2828C49EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls7 deaths44 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 16, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page